Compare Torrent Pharma with Aurobindo Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs AUROBINDO PHARMA - Comparison Results

TORRENT PHARMA     Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TORRENT PHARMA AUROBINDO PHARMA TORRENT PHARMA/
AUROBINDO PHARMA
 
P/E (TTM) x 38.5 19.6 196.7% View Chart
P/BV x 9.8 4.2 230.0% View Chart
Dividend Yield % 0.6 0.2 251.4%  

Financials

 TORRENT PHARMA   AUROBINDO PHARMA
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-19
AUROBINDO PHARMA
Mar-19
TORRENT PHARMA/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs1,964830 236.6%   
Low Rs1,245527 236.2%   
Sales per share (Unadj.) Rs453.4333.9 135.8%  
Earnings per share (Unadj.) Rs25.840.4 63.9%  
Cash flow per share (Unadj.) Rs62.351.8 120.3%  
Dividends per share (Unadj.) Rs17.002.50 680.0%  
Dividend yield (eoy) %1.10.4 287.6%  
Book value per share (Unadj.) Rs279.2237.1 117.8%  
Shares outstanding (eoy) m169.22585.91 28.9%   
Bonus / Rights / Conversions -ESOP-  
Price / Sales ratio x3.52.0 174.1%   
Avg P/E ratio x62.216.8 370.1%  
P/CF ratio (eoy) x25.813.1 196.5%  
Price / Book Value ratio x5.72.9 200.8%  
Dividend payout %65.96.2 1,064.3%   
Avg Mkt Cap Rs m271,513397,569 68.3%   
No. of employees `00013.617.9 76.2%   
Total wages/salary Rs m14,03825,849 54.3%   
Avg. sales/employee Rs Th5,642.610,956.9 51.5%   
Avg. wages/employee Rs Th1,032.41,447.7 71.3%   
Avg. net profit/employee Rs Th320.91,324.3 24.2%   
INCOME DATA
Net Sales Rs m76,728195,636 39.2%  
Other income Rs m5711,553 36.7%   
Total revenues Rs m77,299197,189 39.2%   
Gross profit Rs m19,83139,519 50.2%  
Depreciation Rs m6,1776,680 92.5%   
Interest Rs m5,0382,626 191.8%   
Profit before tax Rs m9,18731,767 28.9%   
Minority Interest Rs m027 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-3,570-881 405.4%   
Tax Rs m1,2547,269 17.2%   
Profit after tax Rs m4,36323,645 18.5%  
Gross profit margin %25.820.2 127.9%  
Effective tax rate %13.622.9 59.6%   
Net profit margin %5.712.1 47.0%  
BALANCE SHEET DATA
Current assets Rs m50,375153,645 32.8%   
Current liabilities Rs m51,653120,429 42.9%   
Net working cap to sales %-1.717.0 -9.8%  
Current ratio x1.01.3 76.4%  
Inventory Days Days92135 68.1%  
Debtors Days Days6864 107.2%  
Net fixed assets Rs m83,648103,909 80.5%   
Share capital Rs m846586 144.4%   
"Free" reserves Rs m46,397138,322 33.5%   
Net worth Rs m47,244138,908 34.0%   
Long term debt Rs m39,1291,800 2,174.4%   
Total assets Rs m141,209264,544 53.4%  
Interest coverage x2.813.1 21.6%   
Debt to equity ratio x0.80 6,393.4%  
Sales to assets ratio x0.50.7 73.5%   
Return on assets %6.79.9 67.0%  
Return on equity %9.217.0 54.3%  
Return on capital %12.323.8 51.7%  
Exports to sales %049.6 0.0%   
Imports to sales %018.8 0.0%   
Exports (fob) Rs mNA97,091 0.0%   
Imports (cif) Rs mNA36,741 0.0%   
Fx inflow Rs m22,10397,316 22.7%   
Fx outflow Rs m5,52240,589 13.6%   
Net fx Rs m16,58156,727 29.2%   
CASH FLOW
From Operations Rs m17,98116,220 110.9%  
From Investments Rs m-2,413-28,768 8.4%  
From Financial Activity Rs m-13,14519,191 -68.5%  
Net Cashflow Rs m2,3806,656 35.8%  

Share Holding

Indian Promoters % 71.5 54.1 132.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 7.0 8.0 88.3%  
FIIs % 12.6 27.7 45.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.8 10.2 86.3%  
Shareholders   26,511 69,601 38.1%  
Pledged promoter(s) holding % 0.0 8.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TORRENT PHARMA With:   CIPLA  PIRAMAL ENTERPRISES  ALKEM LABORATORIES  SHASUN PHARMA  PFIZER  

Compare TORRENT PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Go Airlines Files DRHP, Happiest Minds Q4 Performance, and Buzzing Stocks Today(Pre-Open)

Indian share markets ended on a flat note on Friday. Benchmark indices fluctuated between gains and losses as rising inflation in the US.

Related Views on News

TORRENT PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 27.0% (Quarterly Result Update)

Oct 27, 2020 | Updated on Oct 27, 2020

For the quarter ended September 2020, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 27.0% YoY). Sales on the other hand came in at Rs 20 bn (up 0.6% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 25.6% (Quarterly Result Update)

Sep 15, 2020 | Updated on Sep 15, 2020

For the quarter ended June 2020, AUROBINDO PHARMA has posted a net profit of Rs 8 bn (up 25.6% YoY). Sales on the other hand came in at Rs 59 bn (up 8.8% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 48.6% (Quarterly Result Update)

Jul 31, 2020 | Updated on Jul 31, 2020

For the quarter ended June 2020, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 48.6% YoY). Sales on the other hand came in at Rs 21 bn (up 1.7% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (4QFY20); Net Profit Up 48.2% (Quarterly Result Update)

Jun 5, 2020 | Updated on Jun 5, 2020

For the quarter ended March 2020, AUROBINDO PHARMA has posted a net profit of Rs 9 bn (up 48.2% YoY). Sales on the other hand came in at Rs 62 bn (up 16.4% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 0.5% (Quarterly Result Update)

Feb 7, 2020 | Updated on Feb 7, 2020

For the quarter ended December 2019, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (down 0.5% YoY). Sales on the other hand came in at Rs 58 bn (up 10.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

More Views on News

Most Popular

Is Intraday Trading For You?(Fast Profits Daily)

May 13, 2021

Do you think you have what it takes to be an intraday trader? Find out in this video.

My Secret to Find Breakthrough Stocks(Fast Profits Daily)

May 7, 2021

I've used this trading technique for many years with great success. I'm sharing it with you today.

Are the Stock Markets Deaf to Covid Agony?(Profit Hunter)

May 6, 2021

Why are markets discounting the economic impact of Covid?

The Key to Profit from India's EV Revolution(Profit Hunter)

May 7, 2021

Stocks you must consider investing in before buying your first electric vehicle.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


May 14, 2021 (Close)

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA 5-YR ANALYSIS

COMPARE TORRENT PHARMA WITH

MARKET STATS